ALLIANCEBERNSTEIN HOLDING L.P.
AllianceBernstein (NYSE: AB) reported preliminary assets under management of $909 billion as of July 31, 2026, up from $906 billion at June 30. The firm cited firmwide net inflows despite unfavorable markets. Institutions saw strong inflows tied to a previously announced $12 billion commercial mortgage loans mandate, Private Wealth had modest inflows, and Retail had outflows.
AB Science (Euronext Paris: AB) raised EUR 14.2m via a private placement to fund early steps of a strategic plan due in September. The issue created 23.28m new shares; an existing long-term investor provided EUR 12m. Proceeds target AB8939 in AML and masitinib Phase III in ALS. Cash is about EUR 23m, covering needs beyond 12 months.
Stonehill Charles G.T. sold 5,000 shares of ALLIANCEBERNSTEIN HOLDING L.P. (AB) at $37.17 ($0.19M total) on 2026-08-04.
Over the past 7 days, alphai's AI scored 2 news stories mentioning AB (ALLIANCEBERNSTEIN HOLDING L.P.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent AB coverage spans earnings, financial news and corporate actions.
In the last 30 days, AB insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($186K). The most active reporter was Stonehill Charles G.T. with 1 filing.
AUM ticked up modestly on net inflows, with channel mix shifting toward Institutions and away from Retail.
The raise extends runway and reduces near-term financing risk while advancing two clinical programs, supporting risk-on positioning but dilutive overhang remains.
A routine director open-market sale under a Form 4, with no 10b5-1 plan, but it is not a fundamental company disclosure.
Guidance mix improves near-term earnings visibility via higher performance fees and lower opex, while AUM and Corebridge onboarding drive forward fee base.
Management’s Corebridge-related AUM outlook and expense guidance reduction are likely to support AB’s medium-term earnings power narrative.
alphai scores every news story that mentions AB with an AI model for sentiment and relevance, and aggregates insider trades from ALLIANCEBERNSTEIN HOLDING L.P.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AllianceBernstein (NYSE: AB) reported preliminary assets under management of $909 billion as of July 31, 2026, up from $906 billion at June 30. The firm cited firmwide net inflows despite unfavorable markets. Institutions saw strong inflows tied to a previously announced $12 billion commercial mortgage loans mandate, Private Wealth had modest inflows, and Retail had outflows.
3 min readAB Science (Euronext Paris: AB) raised EUR 14.2m via a private placement to fund early steps of a strategic plan due in September. The issue created 23.28m new shares; an existing long-term investor provided EUR 12m. Proceeds target AB8939 in AML and masitinib Phase III in ALS. Cash is about EUR 23m, covering needs beyond 12 months.
4 min readStonehill Charles G.T. sold 5,000 shares of ALLIANCEBERNSTEIN HOLDING L.P. (AB) at $37.17 ($0.19M total) on 2026-08-04.
1 min readStrategic Execution and Platform Scaling Achieved record AUM of $905 billion, driven by a return to positive organic growth and the strongest gross sales quarter in five years. Reached the $90 billion to $100 billion private markets AUM target more than a year ahead of schedule, validating a multi-year investment strategy in corporate lending and real estate debt.
6 min readAllianceBernstein (AB) discussed Q2 2026 earnings call topics, including expectations for the Equitable Corebridge merger to add about $100B of AUM over a couple of years, with combined general account assets around $350B and separate around $200B. Management cited resilient private wealth adviser productivity, reduced expense guidance by $5-10M, and demand shifts in U.S. taxable fixed income.
6 min readAllianceBernstein Holding LP (AB) reported Q2 net income of $71.7 million, or 77 cents per share. Adjusted earnings were 82 cents per share. Revenue was $1.17 billion, with adjusted revenue of $887.5 million. The article notes AB shares down 1.5% YTD and 12% over 12 months.
1 min readAllianceBernstein (NYSE:AB) reported Q2 flows and earnings-call updates. Alternatives and multi-asset strategies drew over $4B net inflows, while active-equity outflows neared $11B and taxable fixed-income outflows exceeded $4B. Retail gross sales were $31B, yielding $900M net inflows. Private-market AUM rose to $91B. The firm raised 2026 performance-fee outlook to $115M-$135M and cut non-compensation expense guidance to $620M-$640M.
7 min readAdvanced Bionics, a Sonova brand, said the US FDA approved expanded indications for its cochlear implant systems for single-sided deafness (SSD) and asymmetric hearing loss (AHL). The criteria broaden adult and pediatric eligibility, with company-cited research estimating 271,000 to 345,000 US adults with SSD and only 2.1% using CIs among eligible patients.
3 min readALLIANCEBERNSTEIN HOLDING L.P. (AB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.01 2 a2q26earningsrelease.htm EX-99.01 2Q26 RELEASE Document Ioanis Jorgali, Investors 629.213.6139 ioanis.jorgali@alliancebernstein.com Carly Symington, Media 629.213.5568 carly.symington@alliancebernstein.com ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES SECOND QUARTER RESULTS
7 min readAllianceBernstein (NYSE: AB) reported preliminary assets under management of $905 billion at June 30, 2026, up from $899 billion at May end. The rise was attributed mainly to firmwide net inflows, including a large low-fee passive fixed income mandate, with markets having a neutral impact. For Q2 ended June 30, net inflows were $0.7 billion.
2 min read
